Article Text

Download PDFPDF
Portopulmonary hypertension in cirrhosis: the pathogenetic challenge
  1. F Wong
  1. Correspondence to:
    Dr F Wong
    University of Toronto, 9EN/220, Toronto Hospital, 200 Elizabeth St, Toronto, Ontario, Canada; florence.wongutoronto.ca

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We would like to thank Pellicelli (Gut 2004;53:1721) for his interest in our paper on portopulmonary hypertension in cirrhosis with refractory ascites (Gut 2003;52:1355–62).

We acknowledge that our proposal suggesting the role of endothelin 1 (ET-1) in the pathogenesis of portopulmonary hypertension is based on a small number of patients. However, the strong association between the elevated ET-1 levels in the pulmonary artery and the presence of portopulmonary hypertension in these patients would suggest that this is indeed the case. The confirmatory test would be a reduction in pulmonary pressure following blockade of endothelin receptors in the pulmonary circulation. However, this has not …

View Full Text